{"created":"2023-06-20T15:59:48.919840+00:00","id":17897,"links":{},"metadata":{"_buckets":{"deposit":"42c934aa-2507-46ad-8637-3fc63aa14d7a"},"_deposit":{"created_by":53,"id":"17897","owners":[53],"pid":{"revision_id":0,"type":"depid","value":"17897"},"status":"published"},"_oai":{"id":"oai:redcross.repo.nii.ac.jp:00017897","sets":["615:616:678"]},"author_link":["68141","68143","68139","68144","68140","68146","68145","68142"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-11-30","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"65","bibliographicPageStart":"58","bibliographicVolumeNumber":"32","bibliographic_titles":[{"bibliographic_title":"岡山赤十字病院医学雑誌"},{"bibliographic_title":"The Okayama Red Cross Hospital Journal of Medicine","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"分子標的薬，免疫抑制剤，免疫チェックポイント阻害剤による高血糖が増加している．切除不能癌や膠原病関連で使用される機会が増えているが，免疫チェックポイント阻害剤の免疫関連有害事象（irAE）中で内分泌障害の頻度は比較的高く，急激な発症から 1 型および劇症 1 型糖尿病は重症化リスクが高いと考えられる．ほとんどは抗 PD- 1 抗体・抗 PD‐L1 抗体に関連したもので発症頻度は0.2～ 2 ％程度と推定され，投与開始から発症までは 1 週間から 1 年以上までと様々である．mTOR 阻害剤 Everolimus，免疫抑制剤 Tacrolimus による 2型糖尿病性ケトーシス，免疫チェックポイント阻害剤による劇症 1 型糖尿病ケトアシドーシスの特徴と経過に関して報告する．\n","subitem_description_type":"Abstract"}]},"item_10001_heading_23":{"attribute_name":"見出し","attribute_value_mlt":[{"subitem_heading_banner_headline":"原著","subitem_heading_language":"ja"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"岡山赤十字病院"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0915-8073","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"渡辺, 恭子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"牧田, 文子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"宮下, 雄博"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"竹中, 皇"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"蒲生, 直幸"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"小山, 芳伸"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"細川, 忍"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"早川, 信彦"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-02-01"}],"displaytype":"simple","filename":"3210　原著07　渡辺恭子 p.58-65.pdf","filesize":[{"value":"4.9 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"okayama000051","url":"https://redcross.repo.nii.ac.jp/record/17897/files/3210　原著07　渡辺恭子 p.58-65.pdf"},"version_id":"b149a901-219c-46f2-ac06-c74a9fa1d473"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Everolimus","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"mTOR inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Tacrolimus","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"immune checkpoint inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"fulminant type1 diabetes mellitus","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"薬剤性（mTOR 阻害剤，免疫抑制剤，免疫チェックポイント阻害剤による）高血糖の特徴","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"薬剤性（mTOR 阻害剤，免疫抑制剤，免疫チェックポイント阻害剤による）高血糖の特徴"},{"subitem_title":"Characteristics of drug-induced hyperglycemia due to mTOR inhibitors, Immunosuppressants, or Immune checkpoint inhibitors","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"53","path":["678"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-02-01"},"publish_date":"2022-02-01","publish_status":"0","recid":"17897","relation_version_is_last":true,"title":["薬剤性（mTOR 阻害剤，免疫抑制剤，免疫チェックポイント阻害剤による）高血糖の特徴"],"weko_creator_id":"53","weko_shared_id":-1},"updated":"2023-06-20T17:50:36.997019+00:00"}